Skip to main content
. 2019 Oct 21;32(1):57–68. doi: 10.1093/intimm/dxz060

Fig. 3.

Fig. 3.

Recombinant human-activated MMP-9 and -10 reduce levels of membrane-bound (m) PD-L1 on N-MFs. Primary human isolates of N-MFs were treated with MMP-7, -9, -10 or combinations of these MMPs for 3 h as described in Methods, then immunostained and used for multi-color flow cytometry. Condition media from these cultures were used to determine sPD-L1 by PD-L1 singleplex assay. Live events were gated based on forward and side scatters, as well as negativity for the incorporation of the viability dye (conjugated to eFluor™ 780) and were analyzed for the surface expression of mPD-L1 and mPD-L2. (a) Representative histograms of mPD-L1 expression on the surface of N-MFs following treatment with activated MMPs are shown. Summary of the (b) mPD-L1 and (c) sPD-L1 expressed/produced by N-MFs following treatment with activated MMPs. Summary of the (d) mPD-L2 protein expression on surface of N-MFs following treatment with activated MMPs. Data are shown as mean ± SEM, n = 5, *P < 0.05; **P < 0.01; ***P < 0.001.